Global Biosimilar Drug Market Size By Type (Injection, Tablets), By Application (Ankylosing Spondylitis, Tumor), By Region, And Segment Forecasts, 2023 to 2032

The Global Biosimilar Drug Market was valued at USD 21.2 billion in 2023 and is projected to reach USD 78.5 billion by 2031, growing at a CAGR of 17.5% during the forecast period of 2023 to 2031. This growth is primarily driven by the rising prevalence of chronic diseases, the patent expiration of blockbuster biologics, and the increasing demand for cost-effective treatment options. Biosimilars offer a similar efficacy and safety profile as their reference biologics at a lower cost, making them an increasingly attractive choice for healthcare providers and payers.

Drivers:

Patent Expiry of Biologics:

Numerous high-revenue biologic drugs are reaching the end of their patent life, creating opportunities for biosimilars to enter the market and offer comparable alternatives at lower prices.

Rising Incidence of Chronic Diseases:

With increasing cases of cancer, autoimmune disorders, and diabetes worldwide, the demand for affordable biologic therapies is surging, boosting the uptake of biosimilars in clinical settings.

Cost-Effectiveness & Regulatory Support:

Supportive regulatory frameworks in major markets, including the FDA's abbreviated approval pathway and EMA's streamlined procedures, are accelerating biosimilar development and approval processes.

Restraints:

Physician and Patient Reluctance:

Despite clinical equivalence, some healthcare professionals and patients remain skeptical about switching from reference biologics to biosimilars due to concerns about efficacy and immunogenicity.

Stringent Manufacturing Requirements:

The complex nature of biologics manufacturing demands significant investment and strict adherence to quality standards, which can deter new market entrants.

Opportunity:

Emerging Markets Expansion:

Growing healthcare access and increasing government support in Asia-Pacific, Latin America, and Africa offer promising opportunities for biosimilar manufacturers to penetrate underserved regions.

Collaborations and Licensing Agreements:

Strategic partnerships between pharmaceutical companies and biosimilar developers are accelerating R&D and commercialization, expanding global reach and patient access.

Market by System Type Insights:

Based on product type, monoclonal antibodies dominated the biosimilar drug market in 2023, owing to their extensive use in cancer treatment and autoimmune conditions. The monoclonal antibody segment continues to grow due to high therapeutic demand and recent biosimilar approvals. Other prominent segments include insulin, erythropoietin, and granulocyte-colony stimulating factors (G-CSFs), with insulin biosimilars expected to witness the fastest growth due to the rising diabetic population globally.

Market by End-use Insights:

Hospitals accounted for the largest market share in 2023 due to their high patient inflow and preference for cost-effective treatment options. The hospital pharmacy segment continues to dominate as biosimilars are integrated into treatment protocols, especially for oncology and chronic disease management. Retail pharmacies and online channels are also gaining traction as biosimilars become more widely accepted and available.

Market by Regional Insights:

Europe led the global biosimilar drug market in 2023, driven by early regulatory adoption and broad reimbursement policies. North America is rapidly catching up, with the U.S. market witnessing a sharp increase in biosimilar approvals and uptake. Asia-Pacific is poised for the highest CAGR during the forecast period, supported by government initiatives, growing awareness, and a large patient base.

Competitive Scenario:

Key players operating in the Global Biosimilar Drug Market include:

Amgen Inc.

Pfizer Inc.

Sandoz (a Novartis division)

Samsung Bioepis

Biocon Biologics

Celltrion Healthcare

Mylan N.V.

Teva Pharmaceutical Industries

Fresenius Kabi

Coherus BioSciences

These companies are focusing on R&D investment, regional expansion, and strategic collaborations to launch competitive biosimilar portfolios. Notable developments include Pfizer’s launch of multiple oncology biosimilars in the U.S., and Biocon’s approval for insulin glargine in Europe.

Scope of Work – Global Biosimilar Drug Market

Report Metric Details

Market Size (2023) USD 21.2 billion

Projected Market Size (2031) USD 78.5 billion

CAGR (2023–2031) 17.5%

Market Segments By System Type (Monoclonal Antibodies, Insulin, Erythropoietin, G-CSF), By End-use (Hospitals, Retail Pharmacies, Online Pharmacies), By Region

Growth Drivers Patent expiries, rising chronic disease prevalence, cost-effectiveness, regulatory support

Opportunities Expansion in emerging markets, partnerships for R&D and commercialization

Key Market Developments:

August 2023: Amgen launched Amjevita, the first biosimilar to Humira in the U.S., marking a milestone for biosimilar penetration in the American market.

June 2023: Biocon Biologics received EU approval for its insulin biosimilar, expanding its footprint in Europe.

January 2024: Celltrion announced the successful Phase III trials of its biosimilar for ustekinumab, targeting autoimmune disorders.

March 2024: Pfizer launched a new range of oncology biosimilars in Canada and Latin America, enhancing access to affordable cancer care.

FAQs:

1) What is the current market size of the Global Biosimilar Drug Market?

The Global Biosimilar Drug Market was valued at USD 21.2 billion in 2023.

2) What is the major growth driver of the Global Biosimilar Drug Market?

The major growth driver is the patent expiry of high-value biologics and the increasing demand for cost-effective therapeutic alternatives.

3) Which is the largest region during the forecast period in the Global Biosimilar Drug Market?

Europe holds the largest market share, while Asia-Pacific is expected to witness the highest growth rate.

4) Which segment accounted for the largest market share in the Global Biosimilar Drug Market?

Monoclonal antibodies accounted for the largest share by product type, and hospitals led in terms of end-use.

5) Who are the key market players in the Global Biosimilar Drug Market?

Major players include Amgen Inc., Pfizer Inc., Sandoz, Biocon Biologics, Celltrion Healthcare, and Samsung Bioepis.

Let me know if you'd like the report formatted into a Word document or customized further by region or segment.